Exploring the gyrase ATPase domain for tailoring newer anti-tubercular drugs: Hit to lead optimization of a novel class of thiazole inhibitors
- 1 February 2015
- journal article
- Published by Elsevier in Bioorganic & Medicinal Chemistry
- Vol. 23 (3) , 588-601
Abstract
No abstract availableKeywords
This publication has 32 references indexed in Scilit:
- New Drugs for the Treatment of Tuberculosis: Needs, Challenges, Promise, and Prospects for the FutureThe Journal of Infectious Diseases, 2012
- Structure-Based Design of Novel Benzoxazinorifamycins with Potent Binding Affinity to Wild-Type and Rifampin-Resistant Mutant Mycobacterium tuberculosis RNA PolymerasesJournal of Medicinal Chemistry, 2012
- Current Status and Research Strategies in Tuberculosis Drug DevelopmentJournal of Medicinal Chemistry, 2011
- The challenge of new drug discovery for tuberculosisNature, 2011
- Global tuberculosis drug development pipeline: the need and the realityThe Lancet, 2010
- The Population Dynamics and Control of TuberculosisScience, 2010
- Review of knowledge for rational design and identification of anti-tubercular compoundsExpert Opinion on Drug Discovery, 2009
- The new Stop TB Strategy and the Global Plan to Stop TB 2006-20152007
- Drugs for bad bugs: confronting the challenges of antibacterial discoveryNature Reviews Drug Discovery, 2006
- A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosisScience, 2005